683 Capital Management’s Achieve Life Sciences ACHV Stock Holding History

683 Capital Management’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$588K	–	155
2026 Q1	$588K	Sell	200,000 -14,897	-7%	-$66.2K	0.03%	174
2025 Q4	$1.07M	Buy	+214,897	New	+$937K	0.05%	134
2022 Q4	–	Sell	-125,000	Closed	-$413K	–	308
2022 Q3	$413K	Hold	125,000	–	–	0.03%	136
2022 Q2	$610K	Hold	125,000	–	–	0.04%	158
2022 Q1	$946K	Hold	125,000	–	–	0.05%	170
2021 Q4	$973K	Hold	125,000	–	–	0.04%	175
2021 Q3	$1.06M	Hold	125,000	–	–	0.04%	140
2021 Q2	$1.12M	Buy	+125,000	New	+$1.19M	0.04%	145

Other funds holding ACHV

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

683 Capital Management's ACHV Position: Q2 2026 in Review

683 Capital Management sold out of Achieve Life Sciences (ACHV) in Q2 2026, closing a stake of 200,000 shares — an estimated $588K sold.

683 Capital Management first reported a position in ACHV in Q2 2021 and held it in 8 quarters. The position peaked at $1.12M in Q2 2021. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

683 Capital Management reported no remaining Achieve Life Sciences position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 200,000 Achieve Life Sciences shares in Q2 2026, an estimated $588K.
683 Capital Management first reported a position in Achieve Life Sciences in Q2 2021 and held it in 8 quarters.
683 Capital Management's Achieve Life Sciences position peaked at $1.12M in Q2 2021.
111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.